$1 billion peptide deal announced
CordenPharma has signed a multi-year agreement for the contract manufacture of a large-volume launch peptide at its former Roche facility in Boulder, Colorado. This will begin in 2023 and will potentially be worth about $1 billion, depending on actual production levels required. The customer has not been named and no further details are being disclosed.
As part of this, the company will further expand both large- and medium-scale peptide capacity at Colorado and in Frankfurt sites. It is also engaged in a pursuing a large investment programme to expand capacities and technologies in such areas as peptides, lipids and injectables, with an overall planned investment of over €200 million in 2023.
The deal echoes one recently announced by another of the big peptide CDMOs, Bachem. In December, it signed a further work order with an unnamed customer for large volumes of peptides for a minimum total of CHF 1 billion from 2025 to 2029, to be made at a new facility at its main site in Bubendorf, Switzerland. This followed two previous large-volume contracts announced in September worth CHF 175 million in 2023-4.